Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity

The SPD503‐315 clinical program has studied the efficacy, safety, and tolerability of this product in treating symptoms of ADHD in children and adolescents aged 6‐17 through short‐term, placebo‐controlled studies and long‐termn, open‐label studies. This study will more rigorously assess the long‐term maintenance of efficacy using a placebo‐controlled, randomised‐withdrawal design. To date, all of the completed studies conducted as part of the SPD503 proigram have enrolled subjects from the US. This study is designed to evaluate the long‐term maintenance of efficacy of SPD503 for the treatment of ADHD in children aged 6‐17 years in Europe, Australia, Canada and US.